S*BIO's acute leukemia drug enters preclinical trials

3 December 2007

Singapore-based S*BIO has expanded its proprietary pipeline, with a third drug candidate, SB1317, a novel orally-available small-molecule compound targeted for acute leukemias. The agent is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia patients and are associated with a poor prognosis. In addition, over-expression of wild-type Flt3 has been found in acute lymphoblastic leukemia patients. Cyclin-dependent kinases play important roles in cell cycle control. By inhibiting both, SB1317 is a first-in-class drug for relapsed and refractory acute leukemias. It has entered preclinical tests, S*BIO noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight